Literature DB >> 1660505

HCV RNA in serum of asymptomatic blood donors involved in post-transfusion hepatitis (PTH).

E Villa1, I Ferretti, M De Palma, M Melegari, P P Scaglioni, P Trande, C Vecchi, N Fratti, F Manenti.   

Abstract

A group of blood donors involved in post-transfusion hepatitis was investigated for the presence of the anti-HCV antibody and of HCV RNA as a more direct infection marker. RNA was extracted from serum, reverse transcribed and amplified using primers which belonged to the non structural region. The amplified product of the PCR reaction was 582 base pairs. Seven (25.9%) of the 27 blood donors examined were found anti-HCV-positive by ELISA; five (71.4%) of these were HCV RNA positive. Among the 20 anti-HCV-negative blood donors, four (20.0%) were HCV RNA positive. ALT levels were below 45 UI/l in 18 donors, while the other nine had ALTs over the limit accepted for transfusion. The anti-HCV-negative HCV RNA-positive blood donors had normal ALTs. Our study offers a direct explanation for the substantial proportion of residual cases of anti-HCV-positive post-transfusion hepatitis and suggests the necessity of creating a register of blood donors who have at some time presented blood enzyme abnormalities and for whom second level investigations such as HCV RNA should be used.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1660505     DOI: 10.1016/0168-8278(91)90822-s

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study.

Authors:  E Villa; P Trande; A Grottola; P Buttafoco; A M Rebecchi; T Stroffolini; F Callea; A Merighi; L Camellini; P Zoboli; R Cosenza; L Miglioli; P Loria; R Iori; N Carulli; F Manenti
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

2.  Evaluation of third-generation assays for detection of anti-hepatitis C virus (HCV) antibodies and comparison with presence of HCV RNA in blood donors reactive to c100-3 antigen.

Authors:  D Lavanchy; C Mayerat; B Morel; P Schneider; C Zufferey; J J Gonvers; A Pécoud; P C Frei
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

3.  Prospective comparison of whole-blood- and plasma-based hepatitis C virus RNA detection systems: improved detection using whole blood as the source of viral RNA.

Authors:  J T Stapleton; D Klinzman; W N Schmidt; M A Pfaller; P Wu; D R LaBrecque; J q Han; M J Phillips; R Woolson; B Alden
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

4.  Selection of more pathogenic hepatitis C virus genotype II during long-term follow-up of interferon-treated patients.

Authors:  E Villa; P Buttafoco; A Merighi; A Grottola; I Ferretti; A Ferrari; F Callea; P Trande; A M Rebecchi; F Manenti
Journal:  J Mol Med (Berl)       Date:  1995-05       Impact factor: 4.599

Review 5.  Polymerase chain reaction for the diagnosis of viral hepatitis B and C.

Authors:  C Bréchot
Journal:  Gut       Date:  1993       Impact factor: 23.059

Review 6.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

7.  Follow-up study of acute hepatitis C.

Authors:  D Tan; S W Im; W W Peng; M H Ng
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

8.  Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B.

Authors:  E Villa; A Grottola; P Buttafoco; P Trande; A Merighi; N Fratti; Y Seium; G Cioni; F Manenti
Journal:  Dig Dis Sci       Date:  1995-01       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.